about
A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials.Clinical and economic evaluation of laparoscopic surgery compared with medical management for gastro-oesophageal reflux disease: 5-year follow-up of multicentre randomised trial (the REFLUX trial).COST-EFFECTIVENESS OF RADIOFREQUENCY ABLATION VERSUS LASER FOR VARICOSE VEINS.Stapled haemorrhoidopexy for the treatment of haemorrhoids: a systematic review.Modeling the costs and long-term health benefits of screening the general population for risks of cardiovascular disease: a review of methods used in the literature.Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs.Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.Cost-effectiveness analysis of treatments for chronic disease: using R to incorporate time dependency of treatment response.A Procedure for Deriving Formulas to Convert Transition Rates to Probabilities for Multistate Markov Models.Assessing the cost-effectiveness of new pharmaceuticals in epilepsy in adults: the results of a probabilistic decision model.The UK EndoVascular Aneurysm Repair (EVAR) randomised controlled trials: long-term follow-up and cost-effectiveness analysis.The hospital costs of care for stroke in nine European countries.The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial.Long-term cost-effectiveness analysis of endovascular versus open repair for abdominal aortic aneurysm based on four randomized clinical trials.The UK EndoVascular Aneurysm Repair (EVAR) trials: randomised trials of EVAR versus standard therapy.Efficiency, equity, and budgetary policies: informing decisions using mathematical programming.Randomized trial of a brief physiotherapy intervention compared with usual physiotherapy for neck pain patients: Cost-effectiveness analysisSocial determinants of health: an economic perspectiveThe price of innovation - the role of drug pricing in financing pharmaceutical innovation. A conceptual frameworkEconomic evaluation of coronary artery bypass grafting surgery with and without cardiopulmonary bypass: cost-effectiveness and quality-adjusted life years in a randomized controlled trialThe cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial[A comparison of costs and survival in colorectal cancer patients undergoing surgery according to different organizational models]Costs of an early intervention versus a conservative strategy in acute coronary syndromeModelling correlated clinical outcomes in health technology appraisalComment on 'heterogeneity in action: the role of passive personalization in comparative effectiveness research'Cost-utility analysis of a pharmacotherapy follow-up for elderly nursing home residents in SpainCost-effectiveness of treatments for superficial venous reflux in patients with chronic venous ulcerationCost-effectiveness analysis of a randomized clinical trial of early versus deferred endovenous ablation of superficial venous reflux in patients with venous ulcerationBeyond the cost-effectiveness acceptability curve: The appropriateness of rank probabilities for presenting the results of economic evaluation in multiple technology appraisalEarly versus deferred endovenous ablation of superficial venous reflux in patients with venous ulceration: the EVRA RCTA general framework for classifying costing methods for economic evaluation of health care
P50
Q30839137-BFAB443B-A3B6-4DEB-B434-C534CA28D0D1Q33458264-E051516F-4F92-4CB7-AD81-1FAA6A5815CBQ35881279-928197AB-249C-474A-88B5-BAA01C3EA8EFQ37220126-3D125C17-2E5D-480C-B07A-BDA0A7581AA0Q37306497-F36DC64D-A2C3-46AE-B4E3-B325302FB6AFQ37844721-C3BA94D1-E7F5-4111-91D1-0D113E761CB4Q38764032-7CF487A9-DF0A-4A98-A338-51E919B43BA6Q38862695-7D57716E-88E4-41C1-9E18-606B87DDBC7FQ40389543-DBB27525-0E0E-4171-A349-525199C92EA5Q41602354-DC643D73-B2CD-43C3-A4F2-73DAA35DEF45Q46701262-D80CE744-A33F-42A0-8E94-A36B199F2BB5Q47702583-B4079744-5EB0-4CBB-BA4B-74B5225ADFC2Q47721986-76938AB5-1CA4-48AD-969D-C0DEEFBB4C05Q47764566-01D37769-4BA0-46FA-A686-4D5CC41CB15BQ48082105-D8CBB6F2-95D3-4716-8A5F-FE89AD6E222EQ48474802-D49CC53A-7053-4763-9304-0B5A519A1D15Q51918229-E268960B-6DEA-440A-9B2B-4BA7B2D87B94Q56492241-0501EAF9-3B9E-4B75-858D-6531F8205978Q58623004-BD0EEA68-5FF2-42D3-B622-FC4ED0E230EEQ64071294-418D002D-55B0-4CB8-8F57-A0F03011CD7BQ79719881-7E38E4EE-CE2D-4797-9B16-3A2FB476A730Q79934872-B65A18E0-E7A0-4A3A-8AFF-7FF79B8DA421Q80691784-6DFDE378-E209-4EF3-BBCA-3F9D7A718DD7Q80813670-299BC6B8-34DF-41D4-B8DB-C8630CB6C95EQ84939143-396690FA-6609-48B2-9A34-EFB0B1B41340Q87116009-F1F49D19-BEB3-41F9-A65B-E2EBC035C302Q88009333-6750CBB9-A570-4490-B471-5821D14D92B1Q90766184-D8DCDD21-2539-4D18-A817-1B324004C4E2Q91448075-9B2BCD88-6BDA-4064-A149-31DAB43D0670Q91723130-10116C9D-8AF2-4512-B058-56F3EA4C4DC8Q92366521-1E2BF135-B58B-4860-9A2A-C07981E3D6ECQ92786459-DBA9CA3D-1FD7-441E-A86F-5709FFFCA94D
P50
description
investigador
@es
researcher
@en
name
David Epstein
@en
David Epstein
@nl
type
label
David Epstein
@en
David Epstein
@nl
prefLabel
David Epstein
@en
David Epstein
@nl
P31
P496
0000-0002-2275-0916